Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 19 studies | 23% ± 6% | |
CD16-negative, CD56-bright natural killer cell, human | 11 studies | 23% ± 5% | |
gamma-delta T cell | 10 studies | 29% ± 14% | |
CD16-positive, CD56-dim natural killer cell, human | 8 studies | 24% ± 7% | |
mature NK T cell | 4 studies | 20% ± 4% | |
T cell | 4 studies | 18% ± 4% | |
innate lymphoid cell | 4 studies | 19% ± 3% | |
hematopoietic precursor cell | 3 studies | 31% ± 10% |
Insufficient scRNA-seq data for expression of TRGC1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 4329.30 | 243 / 245 | 100% | 540.30 | 502 / 502 |
lung | 100% | 200.40 | 577 / 578 | 31% | 0.89 | 355 / 1155 |
kidney | 82% | 65.37 | 73 / 89 | 39% | 2.15 | 351 / 901 |
breast | 64% | 39.24 | 294 / 459 | 38% | 3.84 | 425 / 1118 |
brain | 89% | 70.88 | 2341 / 2642 | 13% | 0.20 | 93 / 705 |
spleen | 100% | 442.78 | 241 / 241 | 0% | 0 | 0 / 0 |
thymus | 64% | 36.73 | 420 / 653 | 25% | 2.30 | 151 / 605 |
liver | 74% | 34.76 | 168 / 226 | 10% | 0.33 | 39 / 406 |
peripheral blood | 81% | 580.37 | 748 / 929 | 0% | 0 | 0 / 0 |
stomach | 57% | 26.60 | 205 / 359 | 23% | 0.44 | 65 / 286 |
adipose | 75% | 50.33 | 907 / 1204 | 0% | 0 | 0 / 0 |
bladder | 62% | 37.43 | 13 / 21 | 13% | 0.40 | 63 / 504 |
lymph node | 0% | 0 | 0 / 0 | 72% | 2.42 | 21 / 29 |
uterus | 44% | 14.69 | 75 / 170 | 24% | 0.69 | 112 / 459 |
intestine | 54% | 46.59 | 520 / 966 | 12% | 0.21 | 62 / 527 |
tonsil | 0% | 0 | 0 / 0 | 51% | 0.90 | 23 / 45 |
skin | 13% | 4.42 | 242 / 1809 | 29% | 0.75 | 136 / 472 |
esophagus | 26% | 7.65 | 377 / 1445 | 16% | 0.30 | 29 / 183 |
pancreas | 7% | 1.95 | 23 / 328 | 22% | 0.34 | 40 / 178 |
blood vessel | 28% | 13.09 | 379 / 1335 | 0% | 0 | 0 / 0 |
ovary | 15% | 4.97 | 27 / 180 | 4% | 0.07 | 17 / 430 |
heart | 19% | 5.70 | 163 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 12% | 3.15 | 30 / 258 | 2% | 0.06 | 5 / 230 |
eye | 0% | 0 | 0 / 0 | 11% | 0.22 | 9 / 80 |
muscle | 2% | 0.73 | 20 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0046629 | Biological process | gamma-delta T cell activation |
GO_0002250 | Biological process | adaptive immune response |
GO_0050852 | Biological process | T cell receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0042106 | Cellular component | gamma-delta T cell receptor complex |
GO_0036094 | Molecular function | small molecule binding |
Gene name | TRGC1 |
Protein name | T-cell receptor gamma alternate reading frame protein (TARP) T cell receptor gamma constant 1 |
Synonyms | TCRGC1 |
Description | FUNCTION: Constant region of T cell receptor (TR) gamma chain that participates in the antigen recognition . Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair . Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells . Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements . . |
Accessions | A2JGV3 A0A5H1ZRQ6 P0CF51 ENST00000443402.6 |